Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Cnbc · Aug 20, 2026 · 332 words · By Liz Napolitano

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Merck is likely to climb, even as its patent for popular cancer drug Keytruda is getting closer to expiring, according to Morgan Stanley.

Claims checked 8

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Merck is likely to climb, even as its patent for popular cancer drug Keytruda is getting closer to expiring, according to Morgan Stanley.

Why it matters

The investment bank upgraded the stock to overweight from equal weight.

Common ground

It also raised its price target on shares to $179 from $116, implying 17% upside from Wednesday's close "We are constructive that pipeline optionality (including intismeran autogene and sac-TMT for oncology and tulisokibart in [inflammatory bowel disease])…

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says?
What evidence would most clearly confirm or weaken the claim that The investment bank upgraded the stock to overweight from equal weight?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/08/20/merck-is-finding-more-ways-to-boost-its-shares-m…

fact_checkClaims Checked

eFinder analyzed this article and checked 8 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4

verified Verified By Reference 1

cancel Disputed 1

help Insufficient Evidence 1

info Single Source 1

check_circle

Claim 1: “The investment bank upgraded the stock to overweight from equal weight.”

CORROBORATED

Three independent web sources confirm that Morgan Stanley upgraded Merck from Equal Weight to Overweight.

travel_explore

web search NEUTRAL — Morgan Stanley upgraded Merck (MRK) to Overweight from Equal Weight with a price target of $179, up from $116.
https://www.tipranks.com/news/the-fly/merck-upgraded-to-over…

travel_explore

web search NEUTRAL — Investing.com - Morgan Stanley upgraded Merck & Co. (NYSE:MRK) to Overweight from Equalweight on Tuesday and raised its price target to $179 from $116. The firm cited Merck’s capital allocation and bu…
https://www.investing.com/news/analyst-ratings/morgan-stanle…

travel_explore

web search NEUTRAL — Morgan Stanley analyst Terence Flynn upgraded Merck & Co Inc (NYSE: MRK) from Equal-Weight to Overweight and boosted the price target from $116 to $179.
https://www.benzinga.com/analyst-stock-ratings/upgrades/26/0…

check_circle

Claim 2: “It also raised its price target on shares to $179 from $116”

CORROBORATED

Multiple sources explicitly state that Morgan Stanley raised the price target from $116 to $179.

menu_book

wikipedia NEUTRAL — Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.…
https://en.wikipedia.org/wiki/Merck_&_Co.

menu_book

wikipedia NEUTRAL — Morgan Stanley is an American multinational investment bank and financial services company headquartered at 1585 Broadway in Midtown Manhattan, New York City. With offices in 42 countries and more tha…
https://en.wikipedia.org/wiki/Morgan_Stanley

menu_book

wikipedia NEUTRAL — Palantir Technologies Inc. () is an American publicly traded company that develops data integration and analytics software. Palantir is headquartered in Miami, Florida, and was founded in 2003 by Pete…
https://en.wikipedia.org/wiki/Palantir

+ 3 more evidence sources

verified

Claim 3: “On Wednesday, the company unveiled promising late-stage trial results alongside Moderna that sent the stock up 13% — its best day since March 13, 2009.”

VERIFIED BY REFERENCE

While sources confirm a Phase 3 melanoma trial success with Moderna, there is no evidence in the provided results regarding a 13% stock jump on a specific Wednesday or the comparison to March 13, 2009.

menu_book

wikipedia NEUTRAL — The Bank of New York Mellon Corporation, commonly known as BNY or by its prior brand name BNY Mellon, is an American international financial services company headquartered in New York City. BNY was es…
https://en.wikipedia.org/wiki/BNY

menu_book

wikipedia NEUTRAL — Broadcom Inc. is an American multinational designer, developer, manufacturer, and global supplier of a wide range of semiconductor and infrastructure software products. Broadcom's product offerings se…
https://en.wikipedia.org/wiki/Broadcom

menu_book

wikipedia NEUTRAL — COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincia…
https://en.wikipedia.org/wiki/COVID-19_vaccination_in_Canada

+ 3 more evidence sources

check_circle

Claim 4: “The patent for Keytruday is set to expire in 2028.”

CORROBORATED

Multiple independent sources, including a reference to Merck's own 10-K filing, confirm the Keytruda patent expiration in 2028.

menu_book

wikipedia NEUTRAL — Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administere…
https://en.wikipedia.org/wiki/Pembrolizumab

menu_book

wikipedia NEUTRAL — Pembrolizumab/berahyaluronidase alfa, sold under the brand name Keytruda Qlex, is a fixed dose combination medication used for the treatment of many types of solid tumors. It contains pembrolizumab, a…
https://en.wikipedia.org/wiki/Pembrolizumab/berahyaluronidas…

+ 3 more evidence sources

cancel

Claim 5: “the firm's popular immunotherapy treatment Keytruda saw more than $16 billion in sales in the first half of this year”

DISPUTED

The claim states sales were 'more than $16 billion' in the first half of the year, but the specific evidence from a web search states Keytruda generated $15.16 billion in the first half of 2025, which is less than $16 billion.

menu_book

wikipedia NEUTRAL — LifeArc is a British self-funded medical research organisation, with a focus on rare diseases and drug-resistant infections or antimicrobial resistance. It is both a limited company by guarantee and a…
https://en.wikipedia.org/wiki/LifeArc

menu_book

+ 3 more evidence sources

check_circle

Claim 6: “the main U.S. compound patent for Keytruda is set to expire at the end of 2028”

CORROBORATED

Multiple sources confirm the primary U.S. compound/composition patent for Keytruda expires in 2028.

travel_explore

web search NEUTRAL — When does KEYTRUDA's U.S. patent expire? Merck's 2025 Form 10-K lists 2028 for the U.S. compound patent. Does KEYTRUDA revenue disappear in 2028? No. Patent expiration is not the same as immediate rev…
https://www.mexc.co/learn/article/merck-39-s-keytruda-patent…

travel_explore

web search NEUTRAL — Keytruda is on schedule to lose its patent protection in 2028, opening the door to biosimilar competition. With the loss of exclusivity, Keytruda sales are forecasted to decrease to $27.4bn in 2029 , …
https://www.proclinical.com/blogs/2024-2/top-10-drugs-with-p…

travel_explore

web search NEUTRAL — FDA biologic exclusivity has expired, but the key U.S. composition patent is generally associated with a 2028 loss-of-exclusivity date. KEYTRUDA is governed by the Purple Book, not the Orange Book. No…
https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRU…

help

Claim 7: “Of the 32 analysts covering Merck, 24 have a buy or strong buy rating on the stock.”

INSUFFICIENT EVIDENCE

The claim states 24 out of 32 analysts have a buy/strong buy rating. However, provided evidence shows different numbers: one source cites 15 buy ratings out of 23 analysts, and another cites 17 analysts total. No source corroborates the 24/32 figure.

travel_explore

web search NEUTRAL — Based on 17 analysts offering ratings for Merck & Co Inc. Created with Highcharts 9.3.3. Strong Buy.On average, analysts forecast that MRK's EPS will be $9.63 for 2027, with the lowest EPS forecast at…
https://www.wallstreetzen.com/stocks/us/nyse/mrk/stock-forec…

travel_explore

web search NEUTRAL — Based on 23 Wall Street analysts who have issued ratings for Merck & Co., Inc. in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 8 have given a hold ra…
https://www.marketbeat.com/stocks/NYSE/MRK/forecast/

travel_explore

web search NEUTRAL — Merck Buy Rating Reaffirmed as Analyst Highlights Emerging HIV Franchise and Maintains $137 Price Target.What do analysts say about Merck & Company? Merck & Company’s analyst rating consensus is a Str…
https://www.tipranks.com/stocks/it:1mrkx/forecast

info

Claim 8: “Shares of Merck have jumped 45% year to date”

SINGLE SOURCE

Only one web search result mentions the 45% year-to-date surge to $156. Other results discuss different price points (e.g., $58.39 or $60.49), making the 45% figure uncorroborated by a second independent source.

menu_book

wikipedia NEUTRAL — Merck refers primarily to the German Merck family and three companies founded by the family, including: the Merck Group, a German chemical, pharmaceutical and life sciences company founded in 1668 Me…
https://en.wikipedia.org/wiki/Merck

menu_book

wikipedia NEUTRAL — The Merck Manual of Diagnosis and Therapy, referred to as The Merck Manual, is the world's best-selling medical textbook, and the oldest continuously published English language medical textbook. First…
https://en.wikipedia.org/wiki/Merck_Manual_of_Diagnosis_and_…

+ 3 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.